newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary